IMR Press / RCM / Volume 4 / Issue S6 / pii/1561439375083-155510169

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
The Role of the Thiazolidinediones in the Practical Management of Patients With Type 2 Diabetes and Cardiovascular Risk Factors
Show Less
1 Division of Endocrinology and Metabolism, University of California, San Diego, and Veterans Affairs Medical Center, San Diego, CA
Rev. Cardiovasc. Med. 2003, 4(S6), 29–37;
Published: 20 November 2003
The American Diabetes Association's objective for treating patients with type 2 diabetes mellitus is to normalize glycemia and glycosylated hemoglobin concentrations while controlling blood pressure, cholesterol, and other cardiovascular risk factors. This article focuses on the role of thiazolidinediones (TZDs) in the management of patients with type 2 diabetes with comorbid cardiovascular disease. Insulin resistance is one of the earliest and main defects in type 2 diabetes and is strongly linked to comorbid cardiovascular conditions. The TZDs rosiglitazone and pioglitazone work mainly by reducing insulin resistance and may have the potential to alter the natural history of type 2 diabetes and reduce the cardiovascular mortality and morbidity associated with this condition.
Diabetes mellitus
Glycosylated hemoglobin
Insulin resistance
Back to top